Prognostic impact of the cross-sectional area of the erector spinae muscle in patients with pleuroparenchymal fibroelastosis
書誌事項
- 公開日
- 2023-10-12
- 資源種別
- journal article
- 権利情報
-
- https://creativecommons.org/licenses/by/4.0
- https://creativecommons.org/licenses/by/4.0
- DOI
-
- 10.1038/s41598-023-44138-y
- 公開者
- Springer Science and Business Media LLC
説明
<jats:title>Abstract</jats:title> <jats:p> Pleuroparenchymal fibroelastosis (PPFE) progresses slowly but sometimes relatively quickly, leading to decreased activities of daily living (ADL) and muscle weakness. Skeletal muscle atrophy and muscle weakness in chronic obstructive pulmonary disease (COPD) patients may be caused by cachexia and are associated with reduced ADLs and increased risk of death. However, the association between skeletal muscle mass and the prognosis of PPFE patients remains unknown. We retrospectively analysed the clinical significance of the cross-sectional area of the erector spinae muscle (ESM <jats:sub>CSA</jats:sub> ), a skeletal muscle index, and predictors of mortality within 3 years in PPFE 51 patients, idiopathic pulmonary fibrosis (IPF) 52 patients and COPD 62 patients. PPFE patients had significantly lower ESM <jats:sub>CSA</jats:sub> than IPF or COPD patients, and lower ESM <jats:sub>CSA</jats:sub> (< 22.57 cm <jats:sup>2</jats:sup> ) was associated with prognosis within 3 years (log-rank test; p = 0.006), whereas lower body mass index (BMI) showed no association. Multivariate analysis showed that ESM <jats:sub>CSA</jats:sub> was an independent predictor of mortality within 3 years in PPFE patients (hazard ratio, 0.854; 95% confidence interval: 0.737–0.990, p = 0.036). These results suggest the importance of monitoring ESM <jats:sub>CSA</jats:sub> in PPFE patients and that assessing ESM <jats:sub>CSA</jats:sub> in PPFE patients could be a more useful prognostic indicator than BMI. </jats:p>
収録刊行物
-
- Scientific Reports
-
Scientific Reports 13 (1), 2023-10-12
Springer Science and Business Media LLC
